Goodbody Health Share Price (GDBY)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Goodbody Health Limited	AQSE:GDBY	Aquis Stock Exchange	Ordinary Share	GG00BP6KMG85

	Price Change	% Change	Share Price	Shares Traded	Last Trade
	0.00	0.0%	2.50	0.00	16:29:58

Bid Price		Offer Price	High Price	Low Price	Open Price
1.50		4.00	2.50	2.50	2.50

Last Trade Time	Trade Type	Trade Size	Trade Price	Currency
-		0	2.50	GBX

Goodbody Health (GDBY) Latest News

Goodbody Health News

Date	Time	Source	Headline
26/1/2023	21:52	ALNC	TRADING UPDATES: Proton wins order; Caerus Mineral sells assets
26/1/2023	13:00	UKREG	Goodbody Health Limited Partnership to Offer Innovative Cancer Screening
30/12/2022	10:17	ALNC	IN BRIEF: Goodbody Health CFO steps down, remains company secretary
30/12/2022	07:00	UKREG	Goodbody Health Limited Board Changes
16/12/2022	15:19	ALNC	TRADING UPDATES: Voyager Life buys CBD facility from Goodbody Health
16/12/2022	07:00	UKREG	Goodbody Health Limited Divestment of Polish CBD Operations
01/12/2022	14:31	ALNC	TRADING UPDATES: Field Systems widens interim loss due to Covid impact
01/12/2022	07:00	UKREG	Goodbody Health Limited Board Changes
11/11/2022	14:38	ALNC	EARNINGS SUMMARY: Goodbody shifts away from Covid; Beximco profit down
11/11/2022	07:00	UKREG	Goodbody Health Limited Financial Results Q3 2022

More Goodbody Health News

Goodbody Health Investors Goodbody Health Takeover Rumours

Goodbody Health (GDBY) Share Charts 1 Year Goodbody Health Chart
1 Month Goodbody Health Chart	Intraday Goodbody Health Chart

Goodbody Health (GDBY) Discussions and Chat

No Forum Threads FoundAdd a New Thread

Goodbody Health (GDBY) Most Recent Trades

No Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type

View all Goodbody Health trades in real-time

Goodbody Health (GDBY) Top Chat Posts

Top Posts
Posted at 19/1/2022 07:47 by sifi1 Arden Initiating with Buy, 10p PT; Time to move the needle GBDY.PZ We initiate coverage on Goodbody Health Group with a buy rating and 10p price target. Goodbody is a holistic wellness company embarking on an exciting period of growth. It has recently diversified and repositioned its strategy to deepen its clinical offering and take advantage of the long-term structural themes driving customer attitudes to health and wellbeing - which we believe the market is yet to give it value for. With a 40% ROE, Revenue 20A-23E CAGR of 210%, very strong EBITDA growth and at an 85% valuation discount to industry peers (private clinical lab providers), we’re firm in our view that Goodbody offers great long-term value to investors. Buy. Key Investment Rationale. We base our thesis on several key factors: (1) A diversified product portfolio, aided by a strong clinical services segment; (2) A supportive policy environment following the implementation of the NHS Long Term plan and (3) Strong wellness thematic tailwinds Forecasts: growth and profitability to accelerate. We forecast consolidated sales of £16.0m in the upcoming year (FY21E), rising to £35.1m in FY22E and £59.4m in FY23E representing a 3-year CAGR of +210% (FY20A-FY23E). We expect the group to be earnings positive by H1 ’22 and are forecasting an EBITDA 21-23E CAGR of over 300%. We’d expect any margin contractions from changes to mix to be greatly offset by top line increases Valuation and outlook. We base our price target of 10p on an FY2022E P/E of 11x which implies a FY22E EV/EBITDA of 6.8x – a 178% upside to the current price. We believe this to be justified in light of the projected growth (we forecast gross profit will increase at a 21-23E CAGR of +82.3%), strong returns on capital and the potential for significant upside to our numbers. However, we do acknowledge the early staged nature of this strategy, which brings with it some level of execution risk. Upcoming Catalysts. We expect full year results for FY21 and Q1 & Q2 financials to form key near term catalysts. The quarterly results in the 1st half of FY22 will provide added insight into how the Group is progressing in executing on its strategy to penetrate the blood testing market. We lay out further catalysts in more detail in the note. Key Data (GBDY.PZ) Market Capitalisation £10.9m Shares in Issue 302.6m Free Float 65.6% Average Daily Volume (k) 46 12 Month Trading Range 3p - 7p for reference Arden rate a BUY a 10% or greater increase in share price expected over 12 months Read Full Thread Follow Reply
Posted at 18/1/2022 14:25 by sifi1 Since Satvia Wellness changed its name and EPIC to Goodbody Health GDBY we can now post thoughts and comments here !FOLLOWFEED Read Full Thread Follow Reply

Top Posts

Posted at 19/1/2022 07:47 by sifi1

Arden Initiating with Buy, 10p PT; Time to move the needle GBDY.PZ

We initiate coverage on Goodbody Health Group with a buy rating and 10p price target. Goodbody is a holistic wellness company embarking on an exciting period of growth. It has recently diversified and repositioned its strategy to deepen its clinical offering and take advantage of the long-term structural themes driving customer attitudes to health and wellbeing - which we believe the market is yet to give it value for. With a 40% ROE, Revenue 20A-23E CAGR of 210%, very strong EBITDA growth and at an 85% valuation discount to industry peers (private clinical lab providers), we’re firm in our view that Goodbody offers great long-term value to investors. Buy.

Key Investment Rationale. We base our thesis on several key factors: (1) A diversified product portfolio, aided by a strong clinical services segment; (2) A supportive policy environment following the implementation of the NHS Long Term plan and (3) Strong wellness thematic tailwinds

Forecasts: growth and profitability to accelerate. We forecast consolidated sales of £16.0m in the upcoming year (FY21E), rising to £35.1m in FY22E and £59.4m in FY23E representing a 3-year CAGR of +210% (FY20A-FY23E). We expect the group to be earnings positive by H1 ’22 and are forecasting an EBITDA 21-23E CAGR of over 300%. We’d expect any margin contractions from changes to mix to be greatly offset by top line increases

Valuation and outlook. We base our price target of 10p on an FY2022E P/E of 11x which implies a FY22E EV/EBITDA of 6.8x – a 178% upside to the current price. We believe this to be justified in light of the projected growth (we forecast gross profit will increase at a 21-23E CAGR of +82.3%), strong returns on capital and the potential for significant upside to our numbers. However, we do acknowledge the early staged nature of this strategy, which brings with it some level of execution risk.

Upcoming Catalysts. We expect full year results for FY21 and Q1 & Q2 financials to form key near term catalysts. The quarterly results in the 1st half of FY22 will provide added insight into how the Group is progressing in executing on its strategy to penetrate the blood testing market. We lay out further catalysts in more detail in the note.

Key Data (GBDY.PZ)

Market Capitalisation £10.9m

Shares in Issue 302.6m

Free Float 65.6%

Average Daily Volume (k) 46

12 Month Trading Range 3p - 7p

for reference Arden rate a BUY a 10% or greater increase in share price expected over 12 months

Read Full Thread

Posted at 18/1/2022 14:25 by sifi1

Since Satvia Wellness changed its name and EPIC to Goodbody Health GDBY we can now post thoughts and comments here

!FOLLOWFEED

Read Full Thread

Goodbody Health share price data is direct from the London Stock Exchange

Your Recent History

AQSE

GDBY

Goodbody H..

Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Advertise Here

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US

P: V: D:20230130 21:36:38